Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Oncogene-like addiction to aneuploidy in human cancers

ABSTRACT: Oncogene-like addiction to aneuploidy in human cancers

PROVIDER: PRJNA921841 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23013300_1.fastq.gz	Fastqsanger.gz
	SRR23013300_2.fastq.gz	Fastqsanger.gz
	SRR23013301_1.fastq.gz	Fastqsanger.gz
	SRR23013301_2.fastq.gz	Fastqsanger.gz
	SRR23013302_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 103

Similar Datasets

Oncogene-like addiction to aneuploidy in human cancers

Project description:Most cancers exhibit aneuploidy, but its functional significance in tumor development is controversial. Here, we describe ReDACT (Restoring Disomy in Aneuploid cells using CRISPR Targeting), a set of chromosome engineering tools that allow us to eliminate specific aneuploidies from cancer genomes. Using ReDACT, we created a panel of isogenic cells that have or lack common aneuploidies, and we demonstrated that trisomy of chromosome 1q is required for malignant growth in cancers harboring this alteration. Mechanistically, gaining chromosome 1q increases the expression of MDM4 and suppresses TP53 signaling, and we show that TP53 mutations are mutually-exclusive with 1q aneuploidy in human cancers. Thus, specific aneuploidies play essential roles in tumorigenesis, raising the possibility that targeting these “aneuploidy addictions” could represent a novel approach for cancer treatment.

2023-01-09 | GSE222379 | GEO

Mechanism of Oncogene Addiction

Project description:Mechanism of Oncogene Addiction

| PRJNA302297 | ENA

Oncogene-like addiction to aneuploidy in human cancers.

Project description:Most cancers exhibit aneuploidy, but its functional significance in tumor development is controversial. Here, we describe ReDACT (Restoring Disomy in Aneuploid cells using CRISPR Targeting), a set of chromosome engineering tools that allow us to eliminate specific aneuploidies from cancer genomes. Using ReDACT, we created a panel of isogenic cells that have or lack common aneuploidies, and we demonstrate that trisomy of chromosome 1q is required for malignant growth in cancers harboring this alteration. Mechanistically, gaining chromosome 1q increases the expression of MDM4 and suppresses TP53 signaling, and we show that TP53 mutations are mutually-exclusive with 1q aneuploidy in human cancers. Thus, specific aneuploidies play essential roles in tumorigenesis, raising the possibility that targeting these "aneuploidy addictions" could represent a novel approach for cancer treatment.

| S-EPMC9882055 | biostudies-literature

Oncogene-like addiction to aneuploidy in human cancers.

Project description:Most cancers exhibit aneuploidy, but its functional significance in tumor development is controversial. Here, we describe ReDACT (Restoring Disomy in Aneuploid cells using CRISPR Targeting), a set of chromosome engineering tools that allow us to eliminate specific aneuploidies from cancer genomes. Using ReDACT, we created a panel of isogenic cells that have or lack common aneuploidies, and we demonstrate that trisomy of chromosome 1q is required for malignant growth in cancers harboring this alteration. Mechanistically, gaining chromosome 1q increases the expression of MDM4 and suppresses p53 signaling, and we show that TP53 mutations are mutually exclusive with 1q aneuploidy in human cancers. Thus, tumor cells can be dependent on specific aneuploidies, raising the possibility that these "aneuploidy addictions" could be targeted as a therapeutic strategy.

| S-EPMC10753973 | biostudies-literature

An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies

Project description:Oncogene addiction provides important therapeutic opportunities for precision oncology treatment strategies. To date the cellular circuitries associated with driving oncoproteins, which eventually establish the phenotypic manifestation of oncogene addiction remain largely unexplored. We employed a targeted mass spectrometry approach to systematically explore alterations in 116 phosphosites related to oncogene signaling and its intersection with the DDR following inhibition of the addicting oncogene alone or in combination with irradiation in MET-, EGFR-, ALK- or BRAF (V600)-positive cancer models and ex vivo non-small cell lung cancer patient organotypic cultures. We identified an ‘oncogene addiction phosphorylation signature’ (OAPS) consisting of 8 protein phosphorylations (ACLY S455, IF4B S422, IF4G1 S1231, LIMA1 S490, MYCN S62, NCBP1 S22, P3C2A S259 and TERF2 S365) that are significantly suppressed upon targeted oncogene inhibition solely in addicted cell line models and patient tissues. We show that the OAPS is present in patient tissues and the OAPS-derived score strongly correlates with the ex vivo responses to targeted treatments.

2023-03-11 | PXD037406 | Pride

Hypoxia-inducible PRMT2 addiction in cancers

Project description:Hypoxia-inducible PRMT2 addiction in cancers

| PRJNA986065 | ENA

Oncogene addiction to GNAS in GNASR201 mutant tumors

Project description:Oncogene addiction to GNAS in GNASR201 mutant tumors

| PRJNA859019 | ENA

The role of microRNA miR-17-92 in MYC oncogene addiction

Project description:miR-17-92 mediates the MYC oncogene addiction in a conditional mouse lymphoma model. To identify targets of miR-17-92 in this model, miR-17-92 was expressed in the conditional lymphoma cell lines using MSCV-puro. Both control and miR-17-92-expressing conditional lymphoma cell lines were treated with doxycycline (DOX) (20ng/ml) for 48 hours to shut off MYC expression.

2014-05-29 | E-GEOD-57507 | biostudies-arrayexpress

The role of microRNA miR-17-92 in MYC oncogene addiction

2014-05-29 | GSE57507 | GEO

Transcriptional Targeting Of Oncogene Addiction In Medullary Thyroid Cancer

Project description:Transcriptional Targeting Of Oncogene Addiction In Medullary Thyroid Cancer

| PRJNA464052 | ENA